Impact of new developments in antiretroviral treatment on AIDS prevention and care in resource-poor countries

AIDS Patient Care and STDs

Volumn 14, Issue 5, 2000, Pages 251-257

  Colebunders, Robert ^a   Verdonck, Kristien ^a   Nachega, Jean ^a   Kothari, Pravin ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; COST CONTROL; DEVELOPING COUNTRY; HEALTH CARE COST; HEALTH SERVICE; HUMAN; HUMAN CELL; HUMAN TISSUE; LABORATORY DIAGNOSIS; META ANALYSIS; PROTEINASE INHIBITION; VERTICAL TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DEVELOPING COUNTRIES; DISEASE TRANSMISSION, HORIZONTAL; DISEASE TRANSMISSION, VERTICAL; DRUG THERAPY, COMBINATION; FEMALE; HEALTH PLANNING; HUMANS; MALE; MEDICALLY UNDERSERVED AREA; PREGNANCY;

EID: 0034073030     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729100317713     Document Type: Article

References (44)

1. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-454.
2. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 1997;21:1531-1532.
3. Joint United Programme on HIV/AIDS (UNAIDS) and the World Health Organisation Report on the global HIV/AIDS epidemic, 1998.
4. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
5. Katz MH, Gerberding JL. Post-exposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. N Engl J Med 1997;15:1097-1099.
6. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;18:1173-1180.
7. Vernazza PI, Troiani L, Flepp M, et al. Potent antiretroviral treatment results in reduced shedding of HIV-RNA and HIV-RNA in semen. Abstract nr 33606 in Conference Supplement of the 12th World AIDS Conference, Geneva, 1998.
8. Gerberding JL. Prophylaxis for occupational exposure to HIV. Ann Intern Med 1996;6:497-501.
9. The US Public Health Service Update provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to human immunodeficiency virus. MMWR 1996;45(2):468-172.
10. Roland ME, Martin JN, Chernoff D, et al. Pitfalls of HIV RNA testing in the San Francisco post-exposure prevention (PEP) project. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, US, January 31-February 04,1999. Abstract 179.
11. Forsythe S, Gilks S. Economic issues and antiretroviral therapy in developing countries. Trans R Soc Trop Med Hyg 1999;93:1-3.
12. Martin AL. The cost of HIV/AIDS care. In: Mann J, Tarantola D, eds. AIDS in the World II. New York: Oxford University Press, 1996, pp. 390-413.
13. Rawlings JE, Holmes J, Belton B, Selwyn P, Friedland G. Changes in HIV/AIDS patterns of care and estimated costs at an urban medical centre during the era of HAART. Conference Record of the 12th World AIDS Conference, Geneva, 1998. Abstract no. 42430.
14. Bartlett JG, Chaison R, Kerruly J, Moore R. Haart: One of the most cost-effective therapies of the past decade. Conference Supplement of the 12th World AIDS Conference, Geneva, 1998. Abstract no. 24380.
15. Churchill D, Pym A, Coker R. Vancouver: Optimism, but at a cost. Intern J STD AIDS 1996;7:385-387.
16. Van Praag E, Perriens J. Caring for patients with HIV and AIDS in middle income countries. Br Med J 1996;313:440.
17. Adler MW. Antiretrovirals for the developing world. Lancet 1998;351:232.
18. Brazil Acts from the legislative branch of power. Law No. 9, 313 of November 1996.
19. Del Rio C, Cahn P, Friedland G. Antiretroviral therapy in Latin America. Int AIDS Soc Newsletter 1998;10:12-13.
20. Saraceni V, Cortes EEM, Perez M, Abbud S, Neves CGL, Durovni B. Impact of the use of protease inhibitors in newly diagnosed AIDS-related infections in Brazil. Conference Record of the 12th World AIDS Conference, Geneva, 1998. Abstract no. 42317.
21. Eyer-Silva WA, Morais de Sá CA, Pinto JFC, Taboada ALC, Leite CA, Sousa FF. Decline in AIDS-related deaths at a university hospital in Rio de Janeiro, Brazil. Conference Record of the 12th World AIDS Conference, Geneva, 1998. Abstract no. 13176.
22. Kalichman AO, Estevam DL, Souza RA, Caraciolo JM, Xavier ZM. Important reduction in the number of deaths among patients of an AIDS referral center in Sao Paulo, Brazil. Conference Record of the 12th World AIDS Conference, Geneva 1998. Abstract no. 42319.
23. Ardila H. Access to treatment for people living with HIV/AIDS in Colombia. Conference Record of the 12th World AIDS Conference, Geneva 1998. Abstract no. 42316.
24. Carpenter ChCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. JAMA 1998;280(1):78-86.
25. Elford J, Bolding G, Sherr L, Maguire M. New therapies for HIV and sexual risk behaviour among gay men in London, UK. Conference Record of the 12th World AIDS Conference, Geneva 1998. Abstract no. 23106.
26. Dattaray S, Maniar JK. Scenario of antiretroviral therapy (ART) in 25,000 HIV/AIDS individuals in Mumbai, India. Conference Record of the 12th World AIDS Conference, Geneva 1998. Abstract no. 22406.
27. Yurin O, Kravchenko A, Gorbachova E, Pokrovsky VV. Method to decrease of the AZT-treatment cost. Conference Record of the 12th World AIDS Conference, Geneva 1998. Abstract no. 12438.
28. Samuel M, Parameshwari S, Raja D, et al. Evaluation of the efficacy and tolerance of AZT and lamivudine in South Indian HIV-1 infected patients. Conference Record of the 12th World AIDS Conference, Geneva 1998. Abstract no. 60189.
29. Larder BA. Viral resistance and the selection of antiretroviral combinations. J Acquir Immun Defic Syndr Hum Retrovirol 1995;10:S28-S33.
30. Joint United Nationals Programme on HIV/AIDS (UNAIDS) and the World Health Organisation. Guidance modules on antiretroviral treatments WHO/ ASD/98.1 UNAIDS/97.7 (1998).
31. Kouchner B. Speech during the 12th World AIDS Conference, Geneva, 1998.
32. Feregrino-Goyos M, Gomez-Caro WH, Alvarado-Diez R, Mireles-Vieyra Citaid SC, Profin VIH AC. Early Mexican experience with ritonavir treatment in triple combo. AIDS 1996;10(suppl. 3):S27.
33. Shaffer N, Chuachoowong R, Mock PA, et al. Shortcourse zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomised controlled trial. Lancet 1999;353:773-780.
34. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: A randomised trial. Lancet 1999;353:781-785.
35. Dabis F, Msellati P, Meda N. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: A double-blind placebo-controlled multicentre trial. Lancet 1999;353:786-792.
36. Saba J. Interim analysis of early efficacy of three short ZDV/3TC combination regimens to prevent motherto-child transmission of HIV-1: the PETRA trial. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, US, January 31-February 04, 1999. Session 8, abstract S7.
37. Anonymous. Setting a bad example on AIDS. Nature 1998;396:603.
38. Lucas SB, Hounnou A, Peacock CS, et al. The mortality and pathology of HIV disease in a West African city. AIDS 1993;7:1569-1579.
39. Colebunders R, Karita E, Taelman H, Mugyenyi P. Antiretroviral treatment in Africa. AIDS 1997;11: S107-S113.
40. Osborne CM. HIV/AIDS in resource-poor settings: Comprehensive care across a continuum. AIDS 1996;10(suppl. 3):S61-70.
41. Colebunders R, Decock R, Mbeba MJ. Improving the quality of care for persons with HIV infection in sub-Saharan Africa. Trop Geogr Med 1995;2:78-81.
42. Colebunders R, Ndumbe P. Priorities for HIV testing in developing countries? Lancet 1993;342:601-602.
43. Foster SD. Supply and use of essential drugs in subSaharan Africa: Some issues and possible solutions. Soc Sci Med 1991;32(11):1201-1218.
44. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795-802.